AtriCure a ‘very impressive story’ that investors should own, says Piper Jaffray

Piper Jaffray analyst Matt O’Brien reiterated an Overweight rating and $37 price target on AtriCure after the company reported preliminary Q4 results and 2019 revenue guidance above the Street. In a research note to investors, O’Brien states that he is “confident” in the set up for 2019 and that AtriCure is a very impressive story that he thinks investors should own in 2019.
https://thefly.com/landingPageNews.php?id=2844885